top of page

Search Results

Results found for "Can Cao"

  • From Multiplex to Models: Scaling Up GPCR Discovery in the Post-Silo Era

    .” — Tom Sakmar A Use Case for Every Angle Beyond RAMPs, this platform can study: Scaffold protein interactions Kotliar sums it up best: “We went from one receptor to many… and now, from many, we can go back to one

  • The Imprecision Problem: Why Your GPCR Drug Discovery Program Is Off-Track Before It Even Starts

    A GPCR program can have world-class science, top-tier talent, and millions in funding — and still fail Every two-week delay in a DMTA cycle can burn through hundreds of thousands in salaries and overhead. discovery data management  pipeline, teams waste hours cleaning, reconciling, and integrating before they can the momentum your GPCR program needs. 👉 https://calendly.com/drgpcr/yamina-corner Or explore how we can

  • Target Residence Time: The Hidden Driver of In Vivo Efficacy

    receptor environments  amplifies target occupancy, even post-clearance ✅ Insight into why half-life can Drugs with poor pharmacokinetics can outperform flashier compounds by exploiting kinetic environments Why Half-Life Can Lie to You Most teams use systemic half-life as a proxy for action. Only in Terry’s Corner Why Terry’s Corner In a world where drug discovery is evolving faster than most can

  • Curve Shifts Don’t Lie, But Your Eyes Might

    No more guesswork, only decisions you can trust. Scatter can masquerade as signal. Subtle shifts vanish in noise. Instead of relying on debate—or worse, intuition—you can calculate an F-value that objectively shows It gives you the power to compare slopes and elevations statistically—so you can confirm whether your lectures  that sharpen the tools you actually use in discovery A growing on-demand library  of lessons you can

  • Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism

    Schild analysis remains one of the few conceptual anchors that can tell us when “simple” truly is simple—and No reduction  in the maximal response (the receptor can still be fully activated). Curvature  can signify heterogeneous receptors  or mixed response mechanisms. It can uncover what’s really  happening inside a complex system. Schild analysis remains the simplest, most revealing conversation we can have with biology.

  • Targeting Intracellular Allosteric Sites in GPCRs

    These sites act as molecular switches that can modulate receptor activity, providing an untapped opportunity Allosteric ligands can be classified as positive allosteric modulators (PAMs), which increase the receptor Alternatively, they can function as neutral allosteric ligands (NALs), binding to a receptor's allosteric Moreover, they have the potential to enhance target selectivity, which can arise from greater sequence Allosteric agonists binding to intracellular sites can also promote G-protein signaling.

  • Applications of Fluorescent Probes in Confocal Imaging of GPCRs: From Live to Fixed Cells

    This technique can acquire three-dimensional image stacks, facilitating the reconstruction of GPCR distribution This enzyme has been modified so a small molecule will covalently bind to it, which can in turn be attached They can be combined with other ligands and are very interesting in TR-FRET (Time-Resolved Förster Energy It can even study the GPCR distribution within endocytic vesicles and across subcellular compartments

  • Allosteric Binding Demystified: Smarter GPCR Drug Discovery

    In the realm of molecular research, precise interpretation is crucial; a misread curve can lead to lost exposes why traditional displacement logic breaks down in allosteric systems, and how overlooking this can Avoid costly blind spots:  Discover how G protein stoichiometry can dictate whether your assay informs—or Sharpen your discovery decisions ➤ Yamina’s Corner - The Hidden Cost of Busy A GPCR program can collapse—not

  • GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions

    conformations, and the binding of a ligand, as well as interactions with signaling molecules like G proteins, can Natural and synthetic ligands can be categorized into four distinct efficacy classes: 1) full agonists produce the maximal response and can differ in intrinsic efficacy; 2) partial agonists are incapable neutral antagonists have null intrinsic efficacy, thus not affecting receptor signaling activity, and can Moreover, they have the potential to enhance target selectivity, which can arise from greater sequence

  • GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery

    These changes can alter how the receptor talks to G proteins, arrestins, or other receptors. this lecture is how cryptic binding pockets —sites that only exist briefly in certain receptor states—can candidates Underestimation of in vivo potency Kenakin explains why recognizing this phenomenon early can Outdated models can mislead your team, waste your resources, and cost your pipeline months of progress

  • Optimizing HTRF Assays with Fluorescent Ligands: Time-Resolved Fluorescence in GPCR Research

    donors used in this technique have longer half-lives  than other fluorophores (between 300μs–1 ms) and can Quite often, there is a need to amplify the signal  strength to detect them, which can be achieved by They can be combined with second generation acceptors like d2, as well as brighter donors, further increasing It can also be combined with  multiplexing . By using donor-acceptor pairs with different emission spectra that don’t overlap, researchers can design

  • Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence

    Welcome back GPCR lovers, In pharmacology, the wrong interpretation of antagonist behavior can derail Solve the problem of misinterpreting your data by understanding how slow-offset kinetics can mimic classical Avoid the professional threat of flawed data interpretations that can lead to costly dead ends and missed Breakthroughs, Not Breakdowns In the fast-paced world of GPCR drug discovery, the "go fast" mindset can Our content is meticulously vetted and organized to provide clarity and actionable insights that you can

  • Mechanism vs. Assumption: A Model-First Path to Getting GPCR MoA Right

    Hi GPCR Community, If you work on GPCR discovery, you already know: early signals can mislead, and timing Right) Early discovery often serves you overlapping curves and noisy baselines; different mechanisms can Get an answer you can defend. Corner Today ➤ Celtarys Research – Confocal Imaging That Preserves GPCR Function Confocal imaging can Physiological relevance:  Fluorescent ligands can retain receptor integrity—critical when signaling readouts

  • Fentanyl and Xylazine: Why Breathing Fails in Overdose

    With street-level contamination rising faster than medicine can adapt, Catherine’s work shows why overdose Why Oxygen Monitors Can Miss the Danger Perhaps the most unsettling part of Catherine’s work is the disconnect doesn’t fail in a single, predictable way—it collapses through overlapping pathways that no single drug can And the illicit supply is moving faster than clinical medicine can adjust. The question now is whether science and public health can keep up.”

  • Innovative Data-Driven Solutions: The pHSense Revolution

    Even minor adjustments can compromise photophysical properties. The outcome is not just a probe; it’s a tool scientists can trust. Whether in industry or academia, whether overexpressing or not, you can adapt the assay to your system Build or adopt assays that can evolve with your questions—like pHSense.” What’s Next?

  • Maria’s Travel Blogs: ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025

    Here you can find the full program . Figure 1. UIC Student Center East. you forget the importance GPCRs holds in drug development as a whole, and how each and every finding can Now back in Europe, all she can think about is next year’s date, in Dublin, where she is sure she will

  • Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR

    achieve this, the work of Heydenreich et al. (2023) will be analysed to demonstrate how mutagenesis can By identifying key β2AR residues that influence efficacy and potency, pharmaceutical researchers can For example, orthosteric drug design —in which drugs bind to the receptor’s primary active site—can now Alternatively, allosteric modulators , which bind to sites outside the traditional ligand-binding pocket, can Understanding the evolutionary conservation of these residues can lead to the development of drugs that

  • Orthosteric vs Allosteric Interactions— and the pHSense Shift in Internalization

    faster, and stay ahead in GPCR drug discovery with evidence-based insights—no hype, just strategies you can Breakthroughs this week: New work clarifies how active-state GPCR conformations can support coupling Available in four formats, it turns a notoriously tricky measurement into something discovery teams can pharmacology—showing how persistence, precision, and the courage to take on “impossible” chemistry can B y integrating them into GPCR workflows, discovery teams can accelerate identification, characterization

  • Ben Clements on Rescuing Opioids with GPCR Modulators

    Redefining Opioid Pharmacology Ben and his colleagues discovered that PAMs can dramatically increase His work highlights how foundational GPCR science can drive therapeutic innovation.

  • Decoding GPCR Function: The Role of Mutagenesis in Rational Drug Discovery

    “ A substitution of one amino acid by another in a protein can have effects ranging from negligible to While these structural techniques offer significant advantages in drug discovery, no single method can Furthermore, data on the role of specific residues within receptors can provide valuable insights for Through either random or targeted (site-directed) approaches, mutagenesis can provide a comprehensive In summary, mutagenesis can be a critical tool in drug discovery, particularly for studying GPCRs.

  • Chemokine receptor-targeted drug discovery: progress and challenges

    Redundancy can be exemplified by the tumor infiltration of Treg cells which can be driven directly by This redundancy can be seen as problematic in drug discovery as blocking a single receptor might not the chemokine-receptor system, different chemokines are able to activate different pathways, which can Signaling bias can be seen as complex as advantageous since selectively inhibiting certain signaling pathways while sparing others, can prevent some of the negative off-target effects.

  • Artificial intelligence – faster, smarter, cheaper GPCR drug discovery

    assays, signaling assays, cell imaging, protein structure determination, and omics applications, which can Classification: AI models can be used to distinguish GPCRs from non-GPCRs, and to classify GPCRs into Mutations: ML methods can determine stabilising mutations that enable structure determination and can Virtual screening: molecular docking and virtual screening can efficiently analyze large databases of Predicting GPCR properties: AI models can predict various properties of GPCRs, such as ligand binding

  • Decoding Olfactory GPCRs: How AlphaFold and AI Are Changing the Game

    “…now you have a plethora of 400 models that you can start with molecular dynamics, docking, virtual iteratively refining the models with docking and mutagenesis data, they developed predictive pipelines that can

  • GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures

    For complex GPCR systems, this boundary is a strategic advantage: NAMs can only shift an agonist curve Kenakin  showed how the same agonist can behave as near-full, partial, or even silent depending on receptor This is why experts never classify ligands from a single system: The same molecule can occupy different Kenakin  stressed that low-alpha NAMs can resemble competitive antagonists unless deeper kinetic or concentration-range Extremely strong binders can fail in structured tissues because they saturate the periphery and never

  • From Failed Experiments to Predictive GPCR Models

    He emphasizes that not every question can be answered computationally—and that saying “we don’t know” In a field where major publications and grant awards can be rare, finding satisfaction in an optimized Modeling a Career on Your Own Terms Carlsson’s career shows that failures can evolve into strengths and that computational insights can transform how we approach GPCRs. early-career researchers, the takeaway is direct: GPCR drug discovery will increasingly depend on those who can

  • A Note from Yamina: Building the Next Chapter of Dr. GPCR

    Learners can study at their own pace, shape the curriculum, and join live monthly AMA sessions with Dr Our access program for researchers in developing countries  continues as well: eligible scientists can 2026, our focus remains simple: keep building with purpose — strengthening what works, refining what can You can always reach me at hello@DrGPCR.org  — and yes, we read every email.

  • Understanding Enzyme Inhibition In GPCR Discovery Programs

    This week’s feature breaks down exactly how to think about inhibitors with rigor and speed, so you can Why CYP450 allostery can make or break translation from bench to bedside. Now — Premium Members Get Over 50% Discount at Checkout ➤ The Innovation Trap: Why Playing It Safe Can Why micro-domains change what “global” signaling can and can’t explain.

  • Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells

    BBVs are nanoparticles covered with Sf9 cell membranes different from mammalian membranes,[9] which can affect receptors’ properties.[10,11] BBVs also lack downstream signaling components, which can be an The speed of reaching the binding equilibrium is key for this assay, which can be monitored over time Altogether, these aspects hint that the linker design and strategy can provide options for the tuning CELT-419 binding to D3 receptors in cells can be clearly visualized with fluorescence imaging.

  • Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted drug discovery

    While these signaling pathways are highly interconnected, they can also be regulated independently (Kenakin In various pathological conditions, including cancer, aberrant ERK activity can lead to uncontrolled ERK activation pathways can be categorised into two main sub-pathways based on their subcellular localisation The choice of pathway can result in different cellular responses, underscoring the criticality of precise understanding the intricacies of GPCR signaling and utilising advanced assay technologies, researchers can

  • Nanobodies: New Dimensions in GPCR Signaling Research

    They can recognize cryptic epitopes often composed of discontinuous amino acid segments and occur only Nbs can stabilize specific conformations of proteins, including unstable structural intermediates and Generation, selection and functional expression: Nanobodies can be obtained by immunizing a camelid and Combinatorial biology methods such as phage display, yeast display, and ribosome display can be used Most Nbs can be functionally expressed as genetically encoded intrabodies within a eukaryotic cell.

bottom of page